An evolutionary role for HIV latency in enhancing viral transmission.
Products Related to Zika, WestNile, Dengue, Malaria, T.B, Chikungunya, HIV, SARS |
Product# 1039 HIV-1 YU2 (M Tropic)Envelope Glycoprotein gp41 |
Product# 1081 HIV-1 gp120 (ADA) |
Product# 1011 HIV-1 gp120 (subtype C) |
Product# 1031 HIV-1 gp120 (YU2) |
SUMMARY
HIV latency is the chief obstacle to eradicating HIV but is widely believed to be an evolutionary accident providing no lentiviral fitness advantage. However, findings of latency being “hardwired” into HIV’s gene-regulatory circuitry appear inconsistent with latency being an evolutionary accident, given HIV’s rapid mutation rate. Here, we propose that latency is an evolutionary “bet-hedging” strategy whose frequency has been optimized to maximize lentiviral transmission by reducing viral extinction during mucosal infections. The model quantitatively fits the available patient data, matches observations of high-frequency latency establishment in cell culture and primates, and generates two counterintuitive but testable predictions. The first prediction is that conventional CD8-depletion experiments in SIV-infected macaques increase latent cells more than viremia. The second prediction is that strains engineered to have higher replicative fitness—via reduced latency—will exhibit lower infectivity in animal-model mucosal inoculations. Therapeutically, the theory predicts treatment approaches that may substantially enhance “activate-and-kill” HIV-cure strategies.
INTRODUCTION
HIV actively replicates in CD4^{+} T lymphocytes but can also enter a long-lived quiescent state termed proviral latency in memory CD4^{+} T cells (Chun et al., 1997a; Finzi et al., 1997). The population of latently infected cells is relatively small in patients (~1 in 10^{6} CD4^{+} T cells) and does not generate significant viral RNA (Pierson et al., 2000). However, latently infected cells provide a critical viral reservoir, which enables lentiviral persistence even during prolonged antiretroviral therapy (ART). Further, if patients interrupt ART, persisting latent viruses reactivate, driving HIV to pre-treatment viral loads within weeks (Richman et al., 2009). Consequently, latency is the chief barrier to a curative HIV therapy.
While latency enables HIV to avoid extinction during ART, the benefit of latency prior to the ART era—during the centuries of natural lentiviral infections—remains unclear. In fact, latency appears to have been deleterious prior to ART since latently infected cells produce no virus and decrease patient viral loads. Given latency’s reduction of lentiviral replicative fitness, the prevailing hypothesis is that latency is an evolutionary accident—an epiphenomenon that only results when lentiviruses infectCD4^{+} T cells that are transitioning from activated to quiescent memory states (Coffin and Swanstrom, 2013; Eisele and Siliciano, 2012; Han et al., 2007). Latency is therefore viewed to be an infrequent bystander effect that only occurs after a viral-driven adaptive immune response initiates and CD4^{+} T lymphocytes begin to form memory subsets. Yet, a recent study in Rhesus macaques indicates that latency reaches high levels within the first 3 days of infection (Whitney et al., 2014), which is prior to the generation of an SIV-specific adaptive immune response (Kuroda et al., 1999).
If latency were a non-beneficial viral trait or epiphenomenon, one would expect it to have been lost due to natural selection or genetic drift, given lentiviruses’ rapid evolutionary rates. Yet, a companion study (Razooky et al., 2015 [this issue of Cell]) demonstrates that the ability to establish latency is “hardwired” into HIV’s gene-regulatory circuitry. This study matches recent data showing that ~50% of cell-culture infections—in which adaptive immune responses are absent—result in lentiviral latency (Calvanese et al., 2013; Dahabieh et al., 2013). Further, HIV’s auto-regulatory Tat circuit appears optimized to amplify stochastic fluctuations in viral gene expression, producing fluctuations that are sufficient to induce a probabilistic switch to latency (Burnett et al., 2009; Weinberger et al., 2005; Weinberger et al., 2008). In general, stochastic expression noise is thought to be selected against and thus filtered out of regulatory circuits when not beneficial (Batada and Hurst, 2007; Fraser et al., 2004). The persistence of a hardwired latency circuit suggests an unknown selective advantage, which outweighs latency’s putative fitness cost of reducing long-term viral loads.
One possible selective benefit is that—by providing a long-lived viral reservoir—latency could enhance lentiviral survival during unfavorable environmental conditions. Similar “bet-hedging” hypotheses (Cohen, 1966) have been proposed for bacteriophage- γ lysogeny (Arkin et al., 1998) and bacterial persistence (Balaban, 2011). However, lentiviral latency would only provide a bet-hedging advantage if there were risks of viral extinction due to environmental fluctuations. In reality, lentiviruses appear in little danger of population crashes, as they evade immune clearance and maintain high viral loads of ~10^{5} particles/ml of blood plasma for years (and lentiviruses clearly did not evolve under pressure from antiretroviral drugs). Further, lentiviruses only infect a small percentage (~1%–2%) of available target cells, making target-cell fluctuations unimportant during chronic infection. Nevertheless, viral loads remain low during one phase of the lentiviral lifecycle: initial mucosal infection.
The probability of successful mucosal infection is low, with <1% of unprotected sex acts between HIV-discordant couples resulting in self-propagating systemic HIV infections (Fraser et al., 2007; Gray et al., 2001; Wawer et al., 2005). When successful infections do occur, they expand from single founder sequences (Kearney et al., 2009; Keele et al., 2008), indicating that only one variant in the transmitted quasispecies avoids extinction. Further, animal models of HIV capture a consistent ~6 day delay from experimental mucosal inoculation to self-propagating infection (Haase, 2011; Zhang et al., 1999), which implies that the first days of lentiviral infection provide conditions unsuitable for viral growth.
The unfavorable conditions of early lentiviral infections typically occur in the mucosa, where >90% of HIV infections initiate (Haase, 2011). HIV’s evolutionary precursor in non-human primates (SIV) also spreads through mucosal transmission—via sexual activity or fighting with subsequent communal wound licking (Santiago et al., 2005). Mucosal challenge experiments in primates with large inoculations provide direct evidence that the mucosa are initially unfavorable to lentiviral growth: large inoculations of ~10^{9} infectious units (by TCID50) initially burn out within ~5 days (Miller et al., 2005). Quantitatively, each initially infected cell lives for ~1 day (Markowitz et al., 2003), so the number of actively infected cells after 5 days scales with (R_{0}^{muc})^{5} — wherein R_{0}^{muc} is the basic reproductive ratio during early mucosal infection. Since actively infected cells crash within ~5 days (Miller et al., 2005), (R_{0}^{muc})^{5} approaches 0, implying that R_{0}^{muc} < < 1 during initial mucosal infection.
Here, we quantitatively test the hypothesis that latency provides a bet-hedging advantage that increases the probability of successful lentiviral transmission despite reducing viral loads during systemic infection (Figure 1A). The key point is that increasing the probability of latency (p_{lat}) increases the probability that each initially infected cell survives initial mucosal infection. Yet, increasing p_{lat} also decreases viral loads in systemically infected hosts, which reduces the inoculum transmitted to new hosts. With a higher per-cell survival rate but fewer initially infected cells, the question is whether latency’s fitness benefits outweigh its costs—which would establish latency as an evolutionarily beneficial trait that is maintained by natural selection.
RESULTS AND DISCUSSION
Mathematical Models of Lentiviral Transmission and Rationale for Models
Three classes of mathematical models are developed to quantify the net impact of latency on lentiviral transmission (Figure S1). Each class of models generalizes the well-parameterized basic model of viral dynamics (Nowak and May, 2000) to include both proviral latency and the conditions of early mucosal infection (i.e., R_{0}^{muc} < 1) during which latency may be critical (Experimental Procedures).
The first class of models tracks initial lentiviral infection in the mucosa alone (Extended Experimental Procedures, Section A). Given the small numbers of infected cells during initial mucosal infection, the established model of mucosal infection is stochastic (Pearson et al., 2011). We analyze this experimentally parameterized stochastic model—and a deterministic approximation to this model—to quantify how the probability of viral extinction in the mucosa depends on the probability of latency (p_{lat}).
The second class of models extends the single-compartment model into a two-compartment model (Figure 1B) that tracks both initial infection in the mucosa and systemic infection in the lymphoid tissue (Extended Experimental Procedures, Section B). Importantly, the initial and systemic infection model compartments only differ in a single experimentally measured parameter: R_{0} (Figure 1B and Table S1). Collectively, the models predict an optimal value of
The third class of models incorporates a canonical immune response (Nowak and May, 2000) into the two-compartment model (Extended Experimental Procedures, Section C)—since a key difference between cell-culture models and chronic infection is the presence of an adaptive immune response. Each immune parameter added is either tied to a distinct patient-measured value or has been measured previously in the literature (Table S2). With no added free parameters, the immune model fits all available patient data and predicts the same robust
Latency’s Net Evolutionary Impact Is the Product of Its Impact on Both Initial Infection and Systemic Infection
To calculate the optimal p_{lat} value, the two-compartment models track latency’s net evolutionary impact across both mucosal and systemic infections. While the nonlinear models are complex, we decouple latency’s net impact on viral transmission into a product of two factors: (1) the average initial inoculum of infected cells per mucosal inoculation (I_{0}), and (2) the probability that an initially infected cell establishes systemic infection (p_{estab}) (Figure 1A). This product can be derived analytically when the number of infected cells is Poisson distributed and when each infected cell lineage is statistically independent. Under these two assumptions, the probability of lentiviral transmission per-mucosal inoculation (p_{transmission}) reduces to:
The equality in Equation [1] is a direct calculation of the Poisson probability that at least one infected cell in the inoculum I_{0} establishes systemic infection. Critically, p_{transmission} < 10^{−2} since < 1% of lentiviral infections result in self-propagating infections (Gray et al., 2001; Wawer et al., 2005). Given the equality, p_{transmission} < 10^{−2} immediately implies that p_{estab} I_{0} < ~10^{−2}.
Having used the equality to establish that p_{estab} I_{0} < ~10^{−2}, we can discard the quadratic and higher-order terms in the Taylor Series expansion of e^{−pestabI0} with negligible impact. This leads to the subsequent approximation (i.e., linearization) in Equation [1]: p_{transmission} ≈ p_{estab} I_{0}.
Given Equation [1], the overall goal of determining whether latency’s benefits outweigh its costs reduces to quantifying latency’s impact on p_{estab} and I_{0}.
Latency Increases the Probability that an Initially Infected Cell Survives Mucosal Infection and Establishes Systemic Infection
To quantify latency’s impact on p_{estab}, we begin by tracking lentiviral survival during mucosal infection alone. As noted above, the first 5 days of mucosal infection are characterized by a lack of detectable actively infected cells (Li et al., 2005; Miller et al., 2005), indicating that R_{0} in the mucosa (R_{0}^{muc}) is initially < < 1 (Extended Experimental Procedures, Section D). R_{0}^{muc} < < 1 is also consistent with the infrequency of successful mucosal transmissions (p_{transmission} < 0.01) and the ~6-day delay before systemic infection when lentiviral infections do establish (Miller et al., 2005).
Both deterministic differential equations models (Figure 2A) and stochastic Monte-Carlo models (Figures S2A and S2B) capture the fitness advantage of latency in the mucosa. Model simulations are performed with R_{0} < 1 and an inoculated dose of virus that results in a few dozen initially infected cells, matching animal mucosal experiments (Haase, 2011; Miller et al., 2005; Zhang et al., 1999). The quantitative models show that—in the absence of latency—all virions and infected cells are driven extinct in the first 5 days of mucosal infection (Figures 2A, inset, and S2A). In contrast, low levels of latency enable viral survival (Figures 2A and S2B). To test the robustness of these predictions across all R_{0} < 1 and I_{0} < 100, a continuous-time branching-process model was developed (Grimmett and Stirzaker, 1992). The branching-process model (Extended Experimental Procedures, Section A) directly computes the viral extinction probability as a function of time, providing an efficient alternative to averaging thousands of Monte-Carlo simulations for each R_{0} and I_{0}. In the absence of latency, the viral extinction probability approaches 1 by day 5 of mucosal infection, except in the small slice when R_{0} ≈ 1 (Figures S2C and S2D)—which does not match the levels of R_{0} inferred from animal mucosal challenge experiments (Miller et al., 2005).
For completeness, the surviving number of mucosally infected cells was directly computed using a Wright-Fisher model (Hartl and Clark, 2007; Extended Experimental Procedures, Section A). The Wright-Fisher simulations demonstrate that the surviving number of mucosally infected cells increases approximately linearly with p_{lat} for each I_{0} (Figures S2E–S2G). This linear dependence can also be derived analytically. Given that R_{0}^{muc} < < 1 during initial mucosal infection, the majority of latently infected cells are produced in the first generation of infection (Extended Experimental Procedures, Section A). Since these cells are unlikely to reactivate during the short duration of initial infection, the number of latently infected cells that survive mucosal infection is ≈ p_{lat}I_{0}, the latent fraction of the inoculum. Thus, both simulations and analytics indicate that increasing p_{lat} approximately linearly increases the number of infected cells that survive initial mucosal infection.
Given that latency appears to increase viral survival in the early mucosa, we next tested whether latency increases the probability of systemic infection, which mainly occurs in the lymphoid tissue where >98% of CD4^{+} T cells reside (Murphy, 2011). To do so, the Wright-Fisher model was extended into a two-compartment model that directly captures the two typical stages of lentiviral infection: early mucosal infection and systemic (lymphoid) infection (Extended Experimental Procedures, Section B). Only a single parameter value is assumed to differ between the early mucosal and systemic infection compartments. While R_{0}^{muc} is parameterized to be <1, R_{0} during systemic infection in the lymphoid tissue (R_{0}^{LT}) is set to 10 to match its value in chronically infected patients (Nowak and May, 2000).
The two-compartment model fits the available human and animal data of early infections, showing that: (1) only a small fraction of mucosal infections result in systemic infections (Fraser et al., 2007), (2) successful systemic infections emerge after ~5–7 days (Haase, 2011), and (3) systemic infections initiate from single “founder” infected cells (Kearney et al., 2009; Keele et al., 2008). More importantly, the two-compartment model directly shows that latency increases the probability (p_{estab}) of systemic infection—with p_{estab} maximized when p_{lat} > 0.6 (Figure S2H; Extended Experimental Procedures, Section E).
Latency Decreases the Inoculum in a New Host
While increasing p_{lat} increases the probability of systemic lymphoid infection for any given inoculum of initially infected cells (I_{0}), the probability of lentiviral infection also depends on I_{0} itself. Critically, I_{0} is proportional to the viral load of the transmitting patient (Extended Experimental Procedures, Equation S4). Thus, we can quantify latency’s impact on I_{0} by measuring latency’s impact on viral loads in systemically infected patients.
To track latency’s effect on systemic viral loads, we simulated the deterministic model in the lymphoid compartment alone (i.e., R_{0} = 10). Initial mucosal infection was not tracked in these simulations because of the data showing that systemic infections emerge from single “founder” viruses independent of the inoculum (Kearney et al., 2009; Keele et al., 2008). These data indicate that mucosal dynamics affect the probability of systemic infection, but not the level once established. Thus, we assumed the existence of a single founder infected cell and solved Equation [6] numerically. Assuming successful systemic establishment, the systemic infection model shows that increasing p_{lat} decreases long-term viral loads (Figure 2B). Consequently, increasing the frequency of latency (p_{lat}) decreases infection inocula (I_{0}) at the population scale.
The Evolutionarily Optimal Probability of Latency Is ~0.5
Given Equation [1], if latency’s benefit to p_{estab} exceeds its cost to I_{0}, then latency increases the probability of lentiviral transmission (p_{transmission}). Mathematically, this net evolutionary benefit of latency can only occur if the (evolutionarily optimal) value of p_{lat} that maximizes p_{transmission} is greater than 0. Here, we test whether the maximizing value of p_{lat} is greater than 0, directly quantifying latency’s net evolutionary benefit.
We first derive p_{estab} as a function of p_{lat}. After initial mucosal infection, only latently infected cells persist, with the number of surviving latently infected cells defined to be
Equation [2] emerges from the result that only latently infected cells survive initial infection in the mucosa (Figures 2A and S2A–S2E). To demonstrate robustness, below we introduce a “leakage” probability (f_{nonlatent}) that reflects the fraction of systemic infections that are established by non-latent cells—including Langerhans dendritic cells, actively infected cells, and free virions.
We next solve for I_{0} as a function of p_{lat}. As noted above, the average infectious dose (i.e., I_{0}) that can be transmitted to a new individual is directly proportional to the time integral of the viral load— ∫ V(t)dt, Equation [S4]—over the duration of systemic infection (Nowak and May, 2000). Analytically solving this time integral yields (Extended Experimental Procedures, Section B):
The constant term in Equation [3] only implies constant in p_{lat}—it may depend on other parameters. Further, Equation [3] is solved under the assumption that latently infected cells rarely reactivate prior to cell death (i.e., r < < d_{L} in Table S1). This conservative assumption reduces the optimal level of latency by presuming that latently infected cells generally die before contributing to viral loads. Given this maximal fitness cost, latency reduces the reproductive ratio during systemic infection, R_{0}^{LT}, by the factor (1 − p_{lat}).
By combining Equations [1–3], p_{transmission} emerges as a function of p_{lat} (Figure 2C):
Equation [4] shows that, for each value of R_{0}^{LT}, the probability of viral transmission has an optimum at a specific p_{lat}. To analytically derive this optimum, we make the simplifying assumption that p_{react} is constant in p_{lat}. This makes
Strikingly, for a typical value of R_{0}^{LT} ~10 (Nowak and May, 2000),
In agreement with these analytic derivations, numerical solutions also show that p_{transmission} has an optimum at p_{lat} ≈ 0.5 (Figure 2D). The numerical simulations are generated by directly calculating ∫ V(t)dt in model runs, rather than approximating it via Equation [3]. Sensitivity analyses show that this optimum at p_{lat} ≈ 0:5 exists across the entire observed range of R_{0}^{LT} values (Figure 2D).
Large Optimal Latency Probability Is Robust to Changes in Model Assumptions
The main prediction of a large
Strikingly, relaxing other model assumptions increases the large
Simplified Two-Compartment Model Fits the High Frequencies of Latency Measured in Experimental Models
The predicted value of
Mathematical Models Incorporating the Immune Response Are Required to Explain the Divergent Latency Frequencies between Experimental Models and Patients
Unlike early mucosal infections or cell-culture infections, chronic lentiviral infections contain an HIV-specific adaptive immune response (Turnbull et al., 2009). Previous work has shown that this adaptive immune response must be incorporated into the basic model of viral dynamics (De Boer and Perelson, 1998; Nowak and May, 2000) to fit the 2–3 log drop in viral loads between the viral peak during acute infection and the viral set point established during chronic infection (Stafford et al., 2000). We hypothesized that incorporating a canonical adaptive immune response (De Boer and Perelson, 1998; Nowak and May, 2000) would also be necessary to observe the reduced level of latently infected cells documented during chronic infection.
A substantial body of literature suggests that the model assumptions that p_{lat} and r are constant must be relaxed to account for the adaptive immune response. In particular, the activation levels of CD4^{+} T cells appear to increase during chronic infection in vivo, as is measured by the expression levels of three activation markers (Li et al., 2005) and the increased turnover rates of CD4^{+} T cells (Mohri et al., 1998). While the exact mechanism is unknown, one potential driver of CD4^{+} T cell activation is the body’s homeostatic response to the depletion of CD4^{+} T cells during acute infection (Mohri et al., 1998). Another potential mechanism is CD8^{+} T cells’ secreting activating cytokines such as TNF-α (Murphy, 2011). Whatever the mechanism, cellular activation factors sharply decrease p_{lat} and sharply activate HIV transcription (Calvanese et al., 2013; Chun et al., 1998; Siliciano and Greene, 2011), for example, by accumulating transcription factors (e.g., NF-κB) that activate the HIV LTR promoter. Further, in the companion study (Razooky et al., 2015), mathematical modeling shows that cellular activation levels bias HIV circuit output (i.e., p_{lat} and r), even though latency is hardwired into the circuit.
Since an adaptive immune response is associated with an increase in CD4^{+} T cell activation levels (Li et al., 2005) that reduces p_{lat} and increases r (Calvanese et al., 2013; Chun et al., 1998; Siliciano and Greene, 2011), we hypothesized that the adaptive-immune response could be responsible for the reduced p_{lat} levels in chronically infected patients (Figure 3A). This hypothesis was quantitatively tested by allowing p_{lat} and r to vary as functions of the effector CD8^{+} T cell concentration, E[t] (Extended Experimental Procedures, Section C). Before the initiation of the adaptive-immune response (i.e., before chronic infection), the model naturally generates high latency probabilities of ~0.5 and low reactivation rates, as in the simplified models above. However, after the viremia peak, cellular activation (Li et al., 2005) and cell death (Doitsh et al., 2010) become substantial, increasing r(E[t]) to high levels and decreasing p_{lat}(E [t]) to low levels (Figure 3B). As a result, the immune model mechanistically explains the divergent latency frequencies measured between experimental models (cell culture and non-human primates) and chronically infected patients (Figure 3B).
Models Incorporating the Immune Response Fit Available Patient Data while Retaining the Robust Optimal Latency Prediction
While the immune-response model interprets the low levels of p_{lat} measured during chronic infection, validation against all available patient data is a critical test of the model. Thus, wetested whether the model could recapitulate extant patient data on: (1) viral loads before ART (Fraser et al., 2007), (2) effector T cell concentrations before ART (Turnbull et al., 2009), (3) latently infected cells before ART (Chun et al., 1997b), and (4) latently infected cells after ART (Finzi et al., 1999). Strikingly, the extended immune-response model is able to fit these four data plateaus (Figure 4A), using established parameter estimates (Table S2). In particular, the immune- response model reproduces the depressed latent reservoir of ~10^{6} cells measured in chronically infected patients. Further, the model captures the ~1 log drop in the latent reservoir under ART (Figure 4A), because ART leads to antigen depletion. This causes the immune-cell population to contract and the reactivation rate r(t) to decrease to its low background level. To be sure that these fits were not artifacts due to model complexity, we also tested simplified immune response models (Extended Experimental Procedures, Section E). While these simplified models fit the four steady-state plateaus, they cannot reproduce the pre-steady-state kinetics measured in patients (Figure S3). In contrast, the full immune model fits both steady-state and pre-steady-state kinetics (Figure 4A, inset), including the viral decay kinetics measured in patients who undergo ART (Markowitz et al., 2003).
Critically, the level of the adaptive immune response does not change the prediction of the simplified model (i.e., the model without an immune response) that the initial latency probability p_{lat}(0) has a large optimum of ~0.5 (Figures 4B and S3). As a result, the prediction of the high optimal latency probability is directly applicable to natural lentiviral hosts even if they exhibit depressed immune responses. Further, as in the simplified models lacking an immune response, the large
Experimental Depletion of CD8^{+} T Cells in SIV-Infected Macaques Will Increase the Latent Reservoir ~3 Logs More Than Viremia
The immune model argues that CD8^{+} T cells depress the latent reservoir during chronic infection—either directly (e.g., through secreted cytokines) or indirectly (e.g., through activation of downstream cell types that secrete factors). Thus, a direct test of the model can be achieved by depleting CD8^{+} T cells with anti-CD8 antibodies. CD8 depletion should increase the latency probability (p_{lat}) toward its original high value of ~0.5 and concomitantly decrease the reactivation rate (r) toward its original low value. In fact, the model quantitatively predicts the outcome of this experiment. Whereas previous CD8 depletion studies have already measured an ~1–3 log increase in the number of actively infected cells following CD8 depletion in SIV-infected Rhesus macaques (Jin et al., 1999; Metzner et al., 2000; Schmitz et al., 1999), the model predicts that the latent reservoir will increase by ~5 logs following CD8 depletion (Figure 5A). Thus, the increase in the latent reservoir would be ~3 logs greater than the increase in actively infected cells and viremia (Figure 5B). A corollary prediction is that CD8 depletion during early pre-peak infection (Matano et al., 1998), prior to a high-level adaptive immune response, will only increase the latent reservoir ~2- to 3-fold and will thus be harder to reliably measure (Figure S4). Notably, these experimental tests of the model require viral outgrowth assays (Finzi et al., 1997) since directly measuring proviral DNA will only report on actively infected cells, which outnumber latently infected cells by orders of magnitude. A viral outgrowth assay post-CD8 depletion would provide quantitative verification of the model and would consequently test the model’s output that latency is a viral bet-hedging strategy tuned by natural selection.
Viral Strains Engineered to Have Higher Replicative Fitness—via Reduced Latency—Will Exhibit Lower Infectivity in Animal-Model Mucosal Inoculations
A more direct experimental test of the model would involve mucosal challenge experiments using recombinant SIV strains engineered to have substantially reduced latency probabilities. Engineering strains with reduced latency efficiencies appears possible since different HIV-1 clades are already known to exhibit different latency frequencies. These clade-specific differences appear to be driven by cis elements within the HIV-1 LTR (Jeeninga et al., 2008; van der Sluis et al., 2011). The model directly predicts that the reduced-latency recombinants will establish self-propagating systemic infections less frequently than the wild-type strains maintaining high latency frequencies. Further, these reduced latency strains could be quantitatively tested for increased replicative fitnesses via competitive growth assays with wild-type strains. If decreasing latency both increased replicative fitness and decreased successful lentiviral transmission, this would directly show that proviral latency provides a bet-hedging advantage that increases viral transmission despite reducing steady-state viral loads.
Proviral Latency Contrasted with Alternate Mechanisms of Initial Viral Survival
A natural question is whether alternatives to latently infected CD4+ T cells exist that also increase the probability of initial viral survival in the mucosa. One proposed non-latent route is dendritic cell migration from the mucosa to the target-cell rich lymphoid tissue (Kahn and Walker, 1998; Wu and KewalRamani, 2006). More specifically, Langerhans dendritic cells present in the mucosa can be infected by HIV and are prone to migration to the lymphoid tissue, where they can support subsequent dissemination of HIV by cis transfer (Peressin et al., 2014). Yet, Langerhans cells’ dissemination of HIV may be partially blocked by neutralizing antibodies (Su et al., 2012). Follicular dendritic cells may provide another route of viral survival; however, these cells do not migrate to the mucosa (Murphy, 2011). In contrast to dendritic cells, proviral latent cells are neither impacted by neutralizing antibodies (being quiescent) nor blocked by the mucosal barrier, which has been proposed to be a viral bottleneck (Haaland et al., 2009). Latency can thus act as a type of “Trojan horse” for the virus. More fundamentally, even if alternative routes of initial viral survival exist, the results of this study (i.e.,
Suppressing Latent Reactivation in the First Week of Infection Could Substantially Reduce the Latent Reservoir, Enhancing “Kick-and-Kill” Therapy
The model presents a potential therapeutic strategy that exploits the need for latently infected cells to reactivate to both establish systemic infection and dramatically increase the size of the latent reservoir (Figure S5). Thus, if the early reactivation rate were reduced—for example, by suppressing antigen- presenting cell (APC) migration (Peressin et al., 2014) or HIV transcriptional reactivation (Weinberger et al., 2008)—systemic infection would be rendered less likely and the latent reservoir size would be substantially decreased (Figure S5). While a caveat of this proposed approach is detection and treatment within the first week of infection, similar early treatments have been achieved; for a review, see Haase (2011). Critically, a substantially smaller latent reservoir of ~10^{2} cells would require the reactivation of far fewer latent cells by imperfect “shock-and-kill” strategies (Archin et al., 2012; Deeks, 2012). As a result, suppression of reactivation during the first week of infection followed by shock and kill could substantially enhance the chances of HIV eradication.
Implications for Alternate Antiviral Therapy Approaches
A further implication of the result that latency is a hardwired, evolutionarily maintained trait is that it may be easier to control HIV by increasing, rather than purging, the latent reservoir (Dar et al., 2014; Weinberger and Weinberger, 2013; Weinberger et al., 2008). Current shock-and-kill therapies are fighting natural selection in attempting to reactivate each of ~10^{5} latent cells. In contrast, discovering a non-toxic compound that switches 90%–95% of actively infected cells to latency would drive HIV’s basic reproductive ratio (R_{0}) below 1, making HIV infection unsustainable. While still a hypothetical avenue, enhancing viral latency may provide a viable alternative if shock-and-kill strategies fail to achieve their goal of complete eradication.
EXPERIMENTAL PROCEDURES
A Simplified Two-Compartment Model to Quantify the Net Impact of Latency on Lentiviral Transmission
All models described in the main text are variations of the well-parameterized basic model of viral dynamics (Nowak and May, 2000) expanded to include latent infections (Rong and Perelson, 2009a, 2009b; Sedaghat et al., 2007, 2008). Absent an immune response, the deterministic form of the models is captured by the following ordinary differential equations:
In the model above, uninfected “target” cells (T) are produced at rate b, decay at rate d_{T}, and can be infected by virus particles (V) at rate k. Upon viral infection, target cells become either latently infected cells (L) with probability p_{lat} or become actively infected (virus-producing) cells (I) with probability 1 − p_{lat}. Latently infected cells reactivate into actively infected cells at rate r or die at the (slow) rate d_{L}. Actively infected cells produce “burst sizes” of n virions as they die at rate d_{I}. Virions decay at the relatively fast rate c. All parameter values are given in Table S1; Table S2 contains parameters for the model extended to include an adaptive immune response (Extended Experimental Procedures, Section C).
Critically, the infection models can be simplified by re-parameterizing the equations interms of thebasic reproductiveratio:R_{0}=bkn/cd_{T}.This “non-dimensionalization” enables us to capture the disparate dynamics between mucosal infection (Figure 2A) and systemic infection (Figure 2B) by simulating the same model for both infection stages and only varying a single parameter, R_{0}. Further, R_{0}^{muc} is experimentally bounded to be < < 1 from the viral dynamics during initial infection (Miller et al., 2005), and R_{0}^{LT}is similarly measured to be ~10 during systemic infection (Nowak and May, 2000). As a result, no assumptions about unknown parameter values are needed to obtain the optimal latency probability (
ACKNOWLEDGMENTS
Weare grateful to Lani Wu and Stephen Altschuler for input and discussions; to Alan Perelson, Warner Greene, Eric Verdin, Anand Pai, Brandon Razooky, and John Coffin for helpful comments; and to Abhyudai Singh for generating preliminary data. We are also grateful to the graphics department at the Gladstone Institutes for artistic expertise and help with figure schematics. This work was supported by the Alfred P. Sloan Foundation, the Wyss Institute Technology Development Fellowship, the NIH Director’s Pioneer Award Program (DP1 OD017181), as well as NIH awards R21AI109611, F32AI102520, and U19AI096113 as part of the Delaney Collaboratory for AIDS Research and Eradication (CARE).
Footnotes
SUPPLEMENTAL INFORMATION
Supplemental Information includes ^{Extended Experimental Procedures}, five figures, and two tables and can be found with this article online at http://dx.doi.org/10.1016/j.cell.2015.02.017.
REFERENCES
- Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012;487:482–485. [PMC free article] [PubMed] [Google Scholar]
- Arkin A, Ross J, McAdams HH. Stochastic kinetic analysis of developmental pathway bifurcation in phage lambda-infected Escherichia coli cells. Genetics. 1998;149:1633–1648. [PMC free article] [PubMed] [Google Scholar]
- Balaban NQ. Persistence: mechanisms for triggering and enhancing phenotypic variability. Curr. Opin. Genet. Dev. 2011;21:768–775. [PubMed] [Google Scholar]
- Batada NN, Hurst LD. Evolution of chromosome organization driven by selection for reduced gene expression noise. Nat. Genet. 2007;39:945–949. [PubMed] [Google Scholar]
- Burnett JC, Miller-Jensen K, Shah PS, Arkin AP, Schaffer DV. Control of stochastic gene expression by host factors at the HIV promoter. PLoS Pathog. 2009;5:e1000260. [PMC free article] [PubMed] [Google Scholar]
- Calvanese V, Chavez L, Laurent T, Ding S, Verdin E. Dual-color HIV reporters trace a population of latently infected cells and enable their purification. Virology. 2013;446:283–292. [PMC free article] [PubMed] [Google Scholar]
- Chun T-W, Stuyver L, Mizell SB, Ehler LA, Mican JAM, Baseler M, Lloyd AL, Nowak MA, Fauci AS. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA. 1997a;94:13193–13197. [PMC free article] [PubMed] [Google Scholar]
- Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M, Chadwick K, Margolick J, Quinn TC, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997b;387:183–188. [PubMed] [Google Scholar]
- Chun TW, Engel D, Mizell SB, Ehler LA, Fauci AS. Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J. Exp. Med. 1998;188:83–91. [PMC free article] [PubMed] [Google Scholar]
- Coffin J, Swanstrom R. HIV pathogenesis: dynamics and genetics of viral populations and infected cells. Cold Spring Harb. Perspect. Med. 2013;3:a012526. [PMC free article] [PubMed] [Google Scholar]
- Cohen D. Optimizing reproduction in a randomly varying environment. J. Theor. Biol. 1966;12:119–129. [PubMed] [Google Scholar]
- Dahabieh MS, Ooms M, Simon V, Sadowski I. A doubly fluorescent HIV-1 reporter shows that the majority of integrated HIV-1 is latent shortly after infection. J. Virol. 2013;87:4716–4727. [PMC free article] [PubMed] [Google Scholar]
- Dar RD, Hosmane NN, Arkin MR, Siliciano RF, Weinberger LS. Screening for noise in gene expression identifies drug synergies. Science. 2014;344:1392–1396. [PMC free article] [PubMed] [Google Scholar]
- De Boer RJ, Perelson AS. Target cell limited and immune control models of HIV infection: a comparison. J. Theor. Biol. 1998;190:201–214. [PubMed] [Google Scholar]
- Deeks SG. HIV: Shock and kill. Nature. 2012;487:439–440. [PubMed] [Google Scholar]
- Doitsh G, Cavrois M, Lassen KG, Zepeda O, Yang Z, Santiago ML, Hebbeler AM, Greene WC. Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell. 2010;143:789–801. [PMC free article] [PubMed] [Google Scholar]
- Eisele E, Siliciano RF. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity. 2012;37:377–388. [PMC free article] [PubMed] [Google Scholar]
- Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278:1295–1300. [PubMed] [Google Scholar]
- Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 1999;5:512–517. [PubMed] [Google Scholar]
- Fraser HB, Hirsh AE, Giaever G, Kumm J, Eisen MB. Noise minimization in eukaryotic gene expression. PLoS Biol. 2004;2:e137. [PMC free article] [PubMed] [Google Scholar]
- Fraser C, Hollingsworth TD, Chapman R, de Wolf F, Hanage WP. Variation in HIV-1 set-point viral load: epidemiological analysis and an evolutionary hypothesis. Proc. Natl. Acad. Sci. USA. 2007;104:17441–17446. [PMC free article] [PubMed] [Google Scholar]
- Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F, Lutalo T, Li X, vanCott T, Quinn TC Rakai Project Team. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet. 2001;357:1149–1153. [PubMed] [Google Scholar]
- Grimmett G, Stirzaker D. Probability and Random Processes. Second Edition. Oxford University Press; 1992. [Google Scholar]
- Haaland RE, Hawkins PA, Salazar-Gonzalez J, Johnson A, Tichacek A, Karita E, Manigart O, Mulenga J, Keele BF, Shaw GM, et al. Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog. 2009;5:e1000274. [PMC free article] [PubMed] [Google Scholar]
- Haase AT. Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu. Rev. Med. 2011;62:127–139. [PubMed] [Google Scholar]
- Han Y, Wind-Rotolo M, Yang HC, Siliciano JD, Siliciano RF. Experimental approaches to the study of HIV-1 latency. Nat. Rev. Microbiol. 2007;5:95–106. [PubMed] [Google Scholar]
- Hartl DL, Clark AG. Principles of population genetics. Fourth Edition. Sunderland, Mass: Sinauer Associates; 2007. [Google Scholar]
- Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DI, Lai J, Blankson JN, Siliciano JD, Siliciano RF. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell. 2013;155:540–551. [PMC free article] [PubMed] [Google Scholar]
- Jeeninga RE, Westerhout EM, van Gerven ML, Berkhout B. HIV-1 latency in actively dividing human T cell lines. Retrovirology. 2008;5:37. [PMC free article] [PubMed] [Google Scholar]
- Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, Blanchard J, Irwin CE, Safrit JT, Mittler J, Weinberger L, et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 1999;189:991–998. [PMC free article] [PubMed] [Google Scholar]
- Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N. Engl. J. Med. 1998;339:33–39. [PubMed] [Google Scholar]
- Kearney M, Maldarelli F, Shao W, Margolick JB, Daar ES, Mellors JW, Rao V, Coffin JM, Palmer S. Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals. J. Virol. 2009;83:2715–2727. [PMC free article] [PubMed] [Google Scholar]
- Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. USA. 2008;105:7552–7557. [PMC free article] [PubMed] [Google Scholar]
- Kuroda MJ, Schmitz JE, Charini WA, Nickerson CE, Lifton MA, Lord CI, Forman MA, Letvin NL. Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys. J. Immunol. 1999;162:5127–5133. [PubMed] [Google Scholar]
- Li Q, Duan L, Estes JD, Ma ZM, Rourke T, Wang Y, Reilly C, Carlis J, Miller CJ, Haase AT. Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature. 2005;434:1148–1152. [PubMed] [Google Scholar]
- Markowitz M, Louie M, Hurley A, Sun E, Di Mascio M, Perelson AS, Ho DD. A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J. Virol. 2003;77:5037–5038. [PMC free article] [PubMed] [Google Scholar]
- Matano T, Shibata R, Siemon C, Connors M, Lane HC, Martin MA. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J. Virol. 1998;72:164–169. [PMC free article] [PubMed] [Google Scholar]
- Metzner KJ, Jin X, Lee FV, Gettie A, Bauer DE, Di Mascio M, Perelson AS, Marx PA, Ho DD, Kostrikis LG, Connor RI. Effects of in vivo CD8(+) T cell depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J. Exp. Med. 2000;191:1921–1931. [PMC free article] [PubMed] [Google Scholar]
- Miller CJ, Li Q, Abel K, Kim EY, Ma ZM, Wietgrefe S, La Franco-Scheuch L, Compton L, Duan L, Shore MD, et al. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J. Virol. 2005;79:9217–9227. [PMC free article] [PubMed] [Google Scholar]
- Mohri H, Bonhoeffer S, Monard S, Perelson AS, Ho DD. Rapid turnover of T lymphocytes in SIV-infected rhesus macaques. Science. 1998;279:1223–1227. [PubMed] [Google Scholar]
- Murphy K. Janeway’s Immunobiology. Eighth Edition. London, New York: Garland Science; 2011. [Google Scholar]
- Nowak M, May R. Virus dynamics: mathematical principles of immunology and virology. Oxford, New York: Oxford University Press; 2000. [Google Scholar]
- Pearson JE, Krapivsky P, Perelson AS. Stochastic theory of early viral infection: continuous versus burst production of virions. PLoS Comput. Biol. 2011;7:e1001058. [PMC free article] [PubMed] [Google Scholar]
- Peressin M, Proust A, Schmidt S, Su B, Lambotin M, Biedma ME, Laumond G, Decoville T, Holl V, Moog C. Efficient transfer of HIV-1 in trans and in cis from Langerhans dendritic cells and macrophages to autologous T lymphocytes. AIDS. 2014;28:667–677. [PubMed] [Google Scholar]
- Pierson T, McArthur J, Siliciano RF. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu. Rev. Immunol. 2000;18:665–708. [PubMed] [Google Scholar]
- Razooky BS, Pai A, Aull K, Rouzine IM, Weinberger LS. A hardwired HIV latency program. Cell. 2015;160:990–1001. this issue. [PMC free article] [PubMed] [Google Scholar]
- Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science. 2009;323:1304–1307. [PubMed] [Google Scholar]
- Rong L, Perelson AS. Modeling HIV persistence, the latent reservoir, and viral blips. J. Theor. Biol. 2009a;260:308–331. [PMC free article] [PubMed] [Google Scholar]
- Rong L, Perelson AS. Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. PLoS Comput. Biol. 2009b;5:e1000533. [PMC free article] [PubMed] [Google Scholar]
- Santiago ML, Range F, Keele BF, Li Y, Bailes E, Bibollet-Ruche F, Fruteau C, Noë R, Peeters M, Brookfield JF, et al. Simian immunodeficiency virus infection in free-ranging sooty mangabeys (Cercocebus atys atys) from the Taï Forest, Côte d’Ivoire: implications for the origin of epidemic human immunodeficiency virus type 2. J. Virol. 2005;79:12515–12527. [PMC free article] [PubMed] [Google Scholar]
- Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA, Racz P, Tenner-Racz K, Dalesandro M, Scallon BJ, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science. 1999;283:857–860. [PubMed] [Google Scholar]
- Sedaghat AR, Siliciano JD, Brennan TP, Wilke CO, Siliciano RF. Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART. PLoS Pathog. 2007;3:e122. [PMC free article] [PubMed] [Google Scholar]
- Sedaghat AR, Siliciano RF, Wilke CO. Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART. BMC Infect. Dis. 2008;8:2. [PMC free article] [PubMed] [Google Scholar]
- Siliciano RF, Greene WC. HIV latency. Cold Spring Harbor Perspect. Med. 2011;1:a007096. [PMC free article] [PubMed] [Google Scholar]
- Stafford MA, Corey L, Cao Y, Daar ES, Ho DD, Perelson AS. Modeling plasma virus concentration during primary HIV infection. J. Theor. Biol. 2000;203:285–301. [PubMed] [Google Scholar]
- Su B, Xu K, Lederle A, Peressin M, Biedma ME, Laumond G, Schmidt S, Decoville T, Proust A, Lambotin M, et al. Neutralizing antibodies inhibit HIV-1 transfer from primary dendritic cells to autologous CD4 T lymphocytes. Blood. 2012;120:3708–3717. [PubMed] [Google Scholar]
- Turnbull EL, Wong M, Wang S, Wei X, Jones NA, Conrod KE, Aldam D, Turner J, Pellegrino P, Keele BF, et al. Kinetics of expansion of epitope-specific T cell responses during primary HIV-1 infection. J. Immunol. 2009;182:7131–7145. [PubMed] [Google Scholar]
- van der Sluis RM, Pollakis G, van Gerven ML, Berkhout B, Jeeninga RE. Latency profiles of full length HIV-1 molecular clone variants with a subtype specific promoter. Retrovirology. 2011;8:73. [PMC free article] [PubMed] [Google Scholar]
- Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, Kiwanuka N, Kigozi G, Kiddugavu M, Lutalo T, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J. Infect. Dis. 2005;191:1403–1409. [PubMed] [Google Scholar]
- Weinberger AD, Weinberger LS. Stochastic fate selection in HIV-infected patients. Cell. 2013;155:497–499. [PubMed] [Google Scholar]
- Weinberger LS, Burnett JC, Toettcher JE, Arkin AP, Schaffer DV. Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell. 2005;122:169–182. [PubMed] [Google Scholar]
- Weinberger LS, Dar RD, Simpson ML. Transient-mediated fate determination in a transcriptional circuit of HIV. Nat. Genet. 2008;40:466–470. [PubMed] [Google Scholar]
- Whitney JB, Hill AL, Sanisetty S, Penaloza-MacMaster P, Liu J, Shetty M, Parenteau L, Cabral C, Shields J, Blackmore S, et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature. 2014;512:74–77. [PMC free article] [PubMed] [Google Scholar]
- Wu L, KewalRamani VN. Dendritic-cell interactions with HIV: infection and viral dissemination. Nat. Rev. Immunol. 2006;6:859–868. [PMC free article] [PubMed] [Google Scholar]
- Zhang Z, Schuler T, Zupancic M, Wietgrefe S, Staskus KA, Reimann KA, Reinhart TA, Rogan M, Cavert W, Miller CJ, et al. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science. 1999;286:1353–1357. [PubMed] [Google Scholar]